Jazz Change To Account Receivables from 2010 to 2025

JAZZ Stock  USD 121.18  1.44  1.17%   
Jazz Pharmaceuticals Change To Account Receivables yearly trend continues to be fairly stable with very little volatility. Change To Account Receivables will likely drop to about -49 M in 2025. During the period from 2010 to 2025, Jazz Pharmaceuticals Change To Account Receivables regression line of annual values had significance of  0.02 and arithmetic mean of (41,306,383). View All Fundamentals
 
Change To Account Receivables  
First Reported
2007-09-30
Previous Quarter
8.7 M
Current Value
15.6 M
Quarterly Volatility
22.9 M
 
Housing Crash
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Jazz Pharmaceuticals financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Jazz Pharmaceuticals' main balance sheet or income statement drivers, such as Interest Expense of 349.5 M, Other Operating Expenses of 3.9 B or Operating Income of 698.6 M, as well as many indicators such as Price To Sales Ratio of 2.22, Dividend Yield of 0.0 or PTB Ratio of 2.98. Jazz financial statements analysis is a perfect complement when working with Jazz Pharmaceuticals Valuation or Volatility modules.
  
Check out the analysis of Jazz Pharmaceuticals Correlation against competitors.

Latest Jazz Pharmaceuticals' Change To Account Receivables Growth Pattern

Below is the plot of the Change To Account Receivables of Jazz Pharmaceuticals PLC over the last few years. It is Jazz Pharmaceuticals' Change To Account Receivables historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Jazz Pharmaceuticals' overall financial position and show how it may be relating to other accounts over time.
Change To Account Receivables10 Years Trend
Slightly volatile
   Change To Account Receivables   
       Timeline  

Jazz Change To Account Receivables Regression Statistics

Arithmetic Mean(41,306,383)
Coefficient Of Variation(77.42)
Mean Deviation24,529,883
Median(40,132,000)
Standard Deviation31,980,498
Sample Variance1022.8T
Range105M
R-Value(0.58)
Mean Square Error725.7T
R-Squared0.34
Significance0.02
Slope(3,904,016)
Total Sum of Squares15341.3T

Jazz Change To Account Receivables History

2025-49 M
2024-46.7 M
2023-51.9 M
2022-90.1 M
2021-92.7 M
2020-38.6 M
2019-92.3 M

About Jazz Pharmaceuticals Financial Statements

Jazz Pharmaceuticals investors use historical fundamental indicators, such as Jazz Pharmaceuticals' Change To Account Receivables, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Jazz Pharmaceuticals. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Change To Account Receivables-46.7 M-49 M

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Jazz Stock Analysis

When running Jazz Pharmaceuticals' price analysis, check to measure Jazz Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Jazz Pharmaceuticals is operating at the current time. Most of Jazz Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Jazz Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Jazz Pharmaceuticals' price. Additionally, you may evaluate how the addition of Jazz Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.